M&A Deal Summary

Laboratory of America Holdings Acquires Genzyme Genetics

On December 1, 2010, Laboratory Corporation of America Holdings acquired life science company Genzyme Genetics from Genzyme Corp. for 925M USD

Acquisition Highlights
  • This is Laboratory of America Holdings’ 10th transaction in the Life Science sector.
  • This is Laboratory of America Holdings’ 3rd largest (disclosed) transaction.
  • This is Laboratory of America Holdings’ 15th transaction in the United States.
  • This is Laboratory of America Holdings’ 1st transaction in Massachusetts.

M&A Deal Summary

Date 2010-12-01
Target Genzyme Genetics
Sector Life Science
Buyer(s) Laboratory Corporation of America Holdings
Sellers(s) Genzyme Corp.
Deal Type Divestiture
Deal Value 925M USD

Target

Genzyme Genetics

Cambridge, Massachusetts, United States
Genzyme Genetics, is a provider of complex reproductive and oncology testing services and the preferred provider for such services to maternal fetal medicine specialists and obstetrician / gynecologists nationally.

Search 170,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Laboratory Corporation of America Holdings

Burlington, North Carolina, United States

website


Category Company
Founded 1971
SectorTest/Measurement Equipment
Employees67,950
Revenue 16.1B USD (2021)
DESCRIPTION
LabCorp's corporate headquarters in downtown Burlington, North Carolina.
LabCorp's corporate headquarters in downtown Burlington, North Carolina.

LabCorp of America Holdings is a provider of medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp was formed in 1971 and is based in Burlington, North Carolina.


DEAL STATS #
Overall 15 of 41
Sector (Life Science) 10 of 20
Type (Divestiture) 1 of 13
State (Massachusetts) 1 of 4
Country (United States) 15 of 39
Year (2010) 2 of 2
Size (of disclosed) 3 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-07-13 DCL Medical laboratories LLC

Indianapolis, Indiana, United States

DCL Medical laboratories LLC, a women's health-focused laboratory, provides diagnostic and clinical trial testing to physicians, hospitals and pharmaceutical companies throughout the central Midwest.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-06-01 Clearstone Central Laboratories, Inc.

Mississauga, Ontario, Canada

Clearstone Central Laboratories, Inc., is a provider of central laboratory services for late-stage clinical trials.

Buy -

Seller(S) 1

SELLER

Genzyme Corp.

Cambridge, Massachusetts, United States

website


Category Company
Founded 1981
SectorLife Science
DESCRIPTION
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.


DEAL STATS #
Overall 2 of 3
Sector (Life Science) 1 of 1
Type (Divestiture) 2 of 3
State (Massachusetts) 1 of 1
Country (United States) 2 of 2
Year (2010) 2 of 2
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-11-18 Genzyme Corporation’s Diagnostic Product Division

United States

Genzyme Diagnostics is a leading provider of global diagnostic products for diagnostics manufacturers, clinical laboratories and physician offices. Sekisui acquired facilities in the U.S., Canada, Germany and the U.K.

Sell $265M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-10 Genzyme Corp -Cholestagel(R)

Ontario, Canada

Genzyme Corp -Cholestagel(R) Colesevelam is a bile acid sequestrant administered orally. Cholestagel(R) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. Cholestagel(R) is contraindicated in patients with bowel or biliary obstruction. Cholestagel(R) is contraindicated in patients with serum triglyceride (TG) > 500 mg/dL and in patients with a history of hypertiglyceridemia-induced pancreatitis.

Sell R$2M